Oculis to Participate in Upcoming Investor Conferences
Oculis Holding AG (OCS)
Company Research
Source: GlobeNewswire
ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming investor conferences in April. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio. 2026 promises to be a landmark year for the company in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: OCS-01 (DIAMOND Phase 3 trials) topline pivotal results in diabetic macular edema (DME) on track for June 2026; Licaminlimab (PREDICT-1 registrational trial) being evaluated as the first genotype-based development program to drive precision medicine in dry eye disease (DED) with topline results planned around late 2026; Privosegtor (PIONEER program) granted Breakthr
Show less
Read more
Impact Snapshot
Event Time:
OCS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCS alerts
High impacting Oculis Holding AG news events
Weekly update
A roundup of the hottest topics
OCS
News
- Oculis Publishes Invitation to the Annual General MeetingGlobeNewswire
- Oculis (OCS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.MarketBeat
- Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema [Yahoo! Finance]Yahoo! Finance
- Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular EdemaGlobeNewswire
- Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis [Yahoo! Finance]Yahoo! Finance
OCS
Earnings
- 11/10/25 - Beat
OCS
Sec Filings
- 4/21/26 - Form 6-K
- 3/27/26 - Form SCHEDULE
- 3/9/26 - Form 144
- OCS's page on the SEC website